Immune activation predicts dual-target CAR-T success in GBM
June 15, 2026
June 15, 2026
PHILADELPHIA, Pennsylvania, June 15 -- The University of Pennsylvania Perelman School of Medicine posted the following news:
* * *
Immune activation predicts dual-target CAR-T success in GBM
*
Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall surviva . . .
* * *
Immune activation predicts dual-target CAR-T success in GBM
*
Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall surviva . . .